Congratulations to longtime client Simulations Plus (SLP) on its pending acquisition for approximately $375 million in cash by investment firm Altaris LLC. Simulations Plus common stockholders will receive $18.50 per share, representing a premium of 26% to Simulations Plus’ 60-day volume-weighted average price as of June 15, 2026. The transaction, which was unanimously approved by the Simulations Plus Board of Directors, is expected to close in the last quarter of 2026, subject to the approval of the Simulations Plus shareholders and other conditions.

Simulations Plus is a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation and has grown steadily in recent years. Procopio attorneys led by Managing Partner Dennis Doucette have negotiated numerous acquisitions for the company over the years, including Immunetrics, Inc., in 2023 and Pro-ficiency in 2024. Doucette has represented Simulations Plus since their public offering in 1997 and also led the negotiations on this exit, supported by Mergers & Acquisitions practice attorneys including Helen Goldstein, Jennifer Trowbridge, and Gabi Turner.

“The life sciences industry is at an inflection point, as software and services are rapidly evolving toward integrated, AI-driven platforms, cloud-based infrastructure, and more predictable, subscription-based business models,” said Simulations Plus CEO Shawn O’Connor in a press release detailing the transaction. “This transaction provides immediate and certain value to Simulations Plus stockholders, and we believe the transaction will better position us to serve our customers and accelerate innovation across product offerings.”

Altaris, LLC is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. It plans to combine Simulations Plus with Chemical Computing Group (CCG), an existing Altaris portfolio company that provides advanced molecular design software to customers across the pharmaceutical, chemical and materials sectors.

Procopio’s Mergers & Acquisitions practice advises growth and middle-market companies, private equity firms, and other investors on buy-side and sell-side transactions. We regularly represent buyers in stock and asset acquisitions, platform investments, add-on transactions, and strategic combinations, helping clients pursue growth while managing risk and execution. We also advise owners and shareholders in sell-side transactions, including strategic and private equity exits, with a focus on execution, risk allocation, and post-closing outcomes.